DepoMed (DEPO) Price Increases Coming - Janney Montgomery Scott (ENDP) (COLL)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Depomed (DEPO): Tidbits on Cebra from the Pain Conference - UBS
May 23, 2016 9:04 AM EDTUBS DepoMed Inc (NASDAQ: DEPO) analyst, Ami Fadia, saw more detailed data from 4 previously reported studies (cLBP, DPN, Respiratory depression and abuse liability) at the World Institute of Pain Conference (WIP). In the cLBP and DPN studies, the discontinuation rates were higher in the Cebra arms vs. Tapentadol. Further, the 400/600g doses of Cebra were less tolerated than the 200g dose as they had higher discontinuations due to treatment emergent adverse events which could be attributed to the forced... More
